




PATENT
ATTORNEY DOCKET NO. 50026/022002

Certificate of Mailing: Date of Deposit: July 26, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Heidi Wright
Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Munehide Kano et al. Art Unit: 1632
Serial No.: 09/823,699 Examiner: Q. J. Li
Filed: March 30, 2001 Customer No.: 21559

Title: AIDS VIRUS VACCINE USING SENDAI VIRUS VECTOR

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in

payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account
No. 03-2095.

Respectfully submitted,

Date: 26 July 2005



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50026/022002
	Serial No.	09/823,699
	Applicant	Munehide Kano et al.
	Filing Date	March 30, 2001
	Group	1632
	IDS Filed	July 26, 2005

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,766,945	6/16/1998	Miller			
	2002/0098576 A1	7/25/2002	Nagai et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Adachi et al., "Production of Acquired Immunodeficiency Syndrome-Associated Retrovirus in Human and Nonhuman Cells Transfected with an Infectious Molecular Clone", <i>Journal of Virology</i> , 59:284-291 (1986).					
	Allen et al., "Effects of Cytotoxic T Lymphocytes (CTL) Directed Against a Single Simian Immunodeficiency Virus (SIV) Gag CTL Epitope on the Course of SIVmac239 Infection", <i>Journal of Virology</i> , 76:10507-10511 (2002).					
	Allen et al., "Tat-Vaccinated Macaques DoNot Control Simian Immunodeficiency Virus SIVmac239 Replication", <i>Journal of Virology</i> , 76:4108-4112 (2002).					
	Ayyavoo et al., "Construction of Attenuated HIV-1 Accessory Gene Immunization Cassettes", <i>Vaccine</i> , 16:1872-1879 (1998).					
	Ciernik et al., "Induction of Cytotoxic T Lymphocytes and Antitumor immunity with DNA Vaccines Expressing Single T Cell Epitopes ¹ ", <i>Journal of Immunology</i> (1996).					
	Clontech, "BD RetroPack PT67 Cell Line", Online catalog and U.S. Patent No. 5,766,945 (2005),					
	Ensoli et al., "Control of Viral Replication and Disease Onset in Cynomolgus Monkeys by HIV-1 TAT Vaccine", <i>Journal of Biological Regulators and Homeostatic Agents</i> , 14:579-590 (1998).					
	Geffin et al., "Association of Antibody Reactivity to ELDKWA, a Glycoprotein 41 Neutralization Epitope, with Disease Progression in Children Perinatally Infected with HIV Type 1", <i>Aids Research and Human Retroviruses</i> , 14:579-590 (1998).					
	Hurwitz et al., "Intranasal Sendai Virus Vaccine Protects African Green Monkeys from Infection with Human Parainfluenza Virus-Type one", <i>Vaccine</i> , 15:533-540 (1997).					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50026/022002
	Serial No.	09/823,699
	Applicant	Munehide Kano et al.
	Filing Date	March 30, 2001
	Group	1632
	IDS Filed	July 26, 2005

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Ishioka et al., "Utilization of MHC Class I Transgenic Mice for Development of Minigene DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes", <i>Journal of Immunology</i> , 162:3915-3925 (1999).
	Kano et al., "Induction of HIV-1-Specific Neutralizing Antibodies in Mice Vaccinated with a Recombinant Sendai Virus Vector", <i>Jpn. J. Infect. Dis.</i> , 55:59-60 (2002).
	Kato et al, Induction of Gag-Specific T-Cell Responses by Therapeutic Immunization with a Gag-Expressing Sendai Virus Vector in Macaques Chronically Infected with Simian-Human Immunodeficiency Virus", <i>Vaccine</i> , 24:3166-3173 (2005).
	Leung et al, "The Kinetics of Specific Immune Responses in Rhesus Monkeys Inoculated with Live Recombinant BCG Expressing SIV Gag, Pol, Env, and Nef Proteins", <i>Virology</i> , 268:94-103 (2000).
	Matano et al., "Cytotoxic T Lymphocyte-Based Control of Simian Immunodeficiency Replication in a Preclinical AIDS Vaccine Trial", <i>J. Exp. Med.</i> , 199:1709-1718 (2004).
	Matano et al., "No Significant Enhancement of Protection by Tat-Expressing Sendai Viral Vector-Booster in a Macaque AIDS Model", <i>AIDS</i> , 17:1392-1394 (2003).
	Subbramanian et al., "Magnitude and Diversity of Cytotoxic-T-Lymphocyte Responses Elicited by Multiepitope DNA Vaccination in Rhesus Monkeys", <i>Journal of Virology</i> , 77:10113-10118 (2003).
	Takeda et al., Protective Efficacy of an AIDS Vaccine, a Single DNA Priming Followed by a Single Booster with a Recombinant Replication-Defective Sendai Virus Vector, in a Macaques AIDS Model", <i>Journal of Virology</i> , 77:9710-9715 (2003).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	